Cutaneous melanoma is the fifth most prevalent cancer in the United States,^[@bibr1-2473974X20903124]^ and cutaneous melanomas of the head and neck region comprise 25% to 30% of all cases.^[@bibr2-2473974X20903124],[@bibr3-2473974X20903124]^ Wide local excision (WLE) is the gold-standard treatment, with excision margins based on microscopic tumor thickness as recommended by the 2016 National Comprehensive Cancer Network (NCCN) guidelines.^[@bibr4-2473974X20903124]^ Despite established guidelines, surgical excision margins for melanomas of the head and neck have been highly variable in practice due to the significant functional and cosmetic implications of lesions in close proximity to many critical vessels, nerves, and organs.^[@bibr5-2473974X20903124]^ For melanomas of the external ear, a range of surgical margins has been reported, from wedge resection to complete auriculectomy.^[@bibr6-2473974X20903124],[@bibr7-2473974X20903124]^ Historically, excision has included the underlying perichondrium and cartilage in addition to the overlying melanoma lesion.^[@bibr8-2473974X20903124],[@bibr9-2473974X20903124]^ These cartilage-excising approaches limit reconstructive options to basic closure techniques such as the standard wedge closure. On the other hand, a cartilage-sparing approach has the potential to maintain the functional and aesthetic qualities of the external ear by preserving a cartilaginous framework for reconstruction. Here, we examine outcomes of cartilage-sparing excision of external ear melanoma through a single-institution analysis of 8 patients. The primary outcome examined was disease-specific survival and overall survival, with secondary outcome measures of margin status, need for re-resection, locoregional recurrence rate, and distant metastasis rate.

Methods {#section7-2473974X20903124}
=======

A retrospective chart review of patients over the age of 18 diagnosed with melanoma of the external ear was performed after review and approval from the Massachusetts Eye and Ear Human Studies Committee. Patients presented to Massachusetts Eye and Ear for evaluation and follow-up during an 8-year period between 2010 and 2018. Radial and gross margins were based on margins documented in operative reports, with confirmation of margins using pathology reports. The deep margin in all cases was cartilage, with perichondrium included in the resection. All patients who underwent surgery at Massachusetts Eye and Ear had surgery performed by the senior author of the study (K.S.E.). Patients with melanoma in situ or melanoma in a location where a cartilage-sparing technique was not applicable, such as the lobule, were excluded from analysis. Patients with staging ≥T1b melanoma with high-risk features (ie, melanoma depth ≥ 0.75 to 1.0 mm and presence of ulceration or mitoses) were offered sentinel lymph node biopsy (SLNB).

Results {#section8-2473974X20903124}
=======

The mean (SD) age of patients undergoing cartilage-sparing excision of melanoma of the external ear was 53.5 (16.8) years (SE, 5.9; range, 29-76 years) ([**Table 1**](#table1-2473974X20903124){ref-type="table"}). Five of 8 patients were male (63%). The mean (SD) follow-up time was 22.5 (15.1) months (SE, 5.3; range, 3.6-46.2 months). The most common primary site for external ear melanoma was the helix, accounting for 6 of 8 (75%) patients, and the most common histologic subtype was superficial spreading melanoma, accounting for 4 of 8 (50%) cases. The mean (SD) tumor thickness was 1.18 (0.62) mm (SE, 0.22; range, 0.17-2.17), with no ulceration seen in 7 of 8 tumors (88%). Mitotic rate was ≥1 per mm^2^ in 7 of 8 tumors (88%).

###### 

Patient Demographics and Tumor Characteristics (n = 8).

![](10.1177_2473974X20903124-table1)

  Characteristic                                                                      Value
  ----------------------------------------------------------------------------------- -------------
  Age, y                                                                              
   Mean (SD)                                                                          53.5 (16.8)
   SE                                                                                 5.9
   Range                                                                              29-76
  Sex, No. (%)                                                                        
   Male                                                                               5 (63)
   Female                                                                             3 (38)
  Follow-up, mo                                                                       
   Mean (SD)                                                                          22.5 (15.1)
   SE                                                                                 5.3
   Range                                                                              3.6-46.2
  Overall survival, No. (%)                                                           8 (100)
  Disease-specific survival, No. (%)                                                  8 (100)
  Local or regional recurrence, No. (%)                                               1 (12.5)
  Distant metastasis, No. (%)                                                         0
  Primary tumor location, No. (%)                                                     
   Helix                                                                              6 (75)
   Postauricular                                                                      1 (12.5)
   Triangular fossa                                                                   1 (12.5)
  Histologic subtype, No. (%)                                                         
   Superficial spreading tumors                                                       4 (50)
   Unclassified/other tumors                                                          4 (50)
  Ulceration, No. (%)                                                                 
   Absent                                                                             7 (88)
   Present                                                                            1 (13)
  Primary tumor mitotic rate, No. (%)                                                 
   \<1 per mm^2^                                                                      1 (13)
   ≥1 per mm^2^                                                                       7 (88)
  Tumor T stage, No. (%)                                                              
   T1a                                                                                1 (13)
   T1b                                                                                3 (38)
   T2a                                                                                2 (25)
   T2b                                                                                1 (13)
   T3a                                                                                1 (13)
  Lymph node status, No. (%)^[a](#table-fn1-2473974X20903124){ref-type="table-fn"}^   
   Positive                                                                           1 (14)
   Negative                                                                           6 (86)
  Thickness/Breslow depth, mm                                                         
   Mean (SD)                                                                          1.18 (0.62)
   SE                                                                                 0.22
   Range                                                                              0.17-2.17

Lymph node status was based on 7 of 8 cartilage-sparing patients who underwent sentinel lymph node biopsy and/or neck dissection.

All patients underwent a 1-cm surgical margin except for 1 patient who had T3 disease with a tumor thickness of 2.17 mm ([**Table 2**](#table2-2473974X20903124){ref-type="table"}), for which a 2-cm margin was used. All surgical defects were reconstructed during the primary resection using full-thickness skin grafts (FTSGs) ([**Figure 1**](#fig1-2473974X20903124){ref-type="fig"}). One patient had positive surgical margins based on pathology ([**Table 2**](#table2-2473974X20903124){ref-type="table"}), with microscopic evidence of tumor approaching but not invading beyond the deep margin of perichondrium. None of the patients had evidence of direct invasion of cartilage on permanent pathology. No patients received adjuvant therapy.

###### 

Summary of Tumor Characteristics, Surgical Margins, Recurrence, and Mean Follow-up.
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  Cartilage-Sparing Surgical Excision                                                                                                                                    
  ------------------------------------- ------ ---------- --------- ------------------- -------------- ---------------------- --------- ----- ---------- --------------- ------
  50/M                                   0.17   No/0/NA    T1aN0M0   Triangular fossa    Unclassified        WLE, FTSG         1 (0.5)   0.2   Negative        No         11.2
  55/F                                   1.0    No/2/No    T1bN0M0         Helix             SSM          WLE, SLNB, FTSG      1 (0.5)   0.4   Negative        No         3.6
  29/F                                   0.78   No/3/NA    T1bN0M0         Helix         Unclassified     WLE, SLNB, FTSG      1 (0.9)   0.2   Negative        No         28.9
  34/F                                   1.55   No/1/NA    T2aN0M0         Helix         Unclassified   WLE, SLNB, SND, FTSG    1 (1)    0.2   Negative        No         4.3
  49/M                                   0.9    No/2/NA    T1bN0M0         Helix              NA          WLE, SLNB, FTSG      1 (NA)    0.2   Negative        No         25.7
  73/M                                   1.2    Yes/2/No   T2bN0M0         Helix             SSM          WLE, SLNB, FTSG      1 (0.9)   0.3   Negative        No         46.2
  62/M                                   2.17   No/10/No   T3aN0M0         Helix             SSM          WLE, SLNB, FTSG      2 (1.4)   NA    Negative        No         24.5
  76/M                                   1.7    No/5/No    T2aN2M0   Posterior auricle       SSM        WLE, SLNB, FTSG, SND   1 (0.6)   0.1   Positive   Yes (33.6 mo)   35.2

Abbreviations: FTSG, full-thickness skin graft; LR/RR, local recurrence/regional recurrence; NA, not available; NV, neurovascular; SLNB, sentinel lymph node biopsy; SND, selective neck dissection; SSM, superficial spreading melanoma; WLE, wide local excision.

Radial margins are based on gross margins described in the operative report, with final radial margins based on the pathology report in parentheses.

![Postoperative photo of cartilage-sparing excision of melanoma of the superior helix with primary reconstruction using a full-thickness skin graft. (A) En face view. (B) Oblique view.](10.1177_2473974X20903124-fig1){#fig1-2473974X20903124}

Seven of 8 patients (88%) underwent SLNB ([**Table 2**](#table2-2473974X20903124){ref-type="table"}). One patient had positive SLNB (2 of 15 nodes) with positive surgical margins as above. This patient also had subsequent local recurrence at 33.6 months, which was excised including the underlying cartilage with completion neck dissection also performed. No additional pathologic nodes were identified ([**Table 2**](#table2-2473974X20903124){ref-type="table"}). No patients had distant metastasis. Overall and disease-specific survival were 100% during the follow-up period for all patients.

Discussion {#section9-2473974X20903124}
==========

Large studies of the optimal surgical management of melanoma of the external ear are lacking, but recent literature suggests that the prognosis of this tumor may be more favorable than previously thought. Less aggressive surgical approaches have become increasingly common.^[@bibr6-2473974X20903124][@bibr7-2473974X20903124]-[@bibr8-2473974X20903124]^ In this small series, we report 100% overall and disease-specific survival over a mean follow-up time of 22.5 months and a 12.5% recurrence rate, with no recurrences among node-negative patients, suggesting that cartilage-sparing excision can provide good oncologic control while enabling reconstructive options with the potential for better aesthetic outcomes.

The existing melanoma literature assumes a standard deep margin of excision to the next fascial layer, which is perichondrium in the case of the external ear.^[@bibr10-2473974X20903124]^ Based on histopathologic examination of ear melanoma resection specimens, invasion of the cartilage is rare, even in melanomas as thick as 11 mm.^[@bibr11-2473974X20903124],[@bibr12-2473974X20903124]^ Theoretically, excising down to the level of the cartilage---by removing the tough perichondrial layer while preserving the cartilage itself---should provide equivalent primary tumor disease control to cartilage removal and should similarly capture any adjacent areas containing lymphatics. In the 1 local recurrence of this series, pathologic analysis of the recurrent lesion found no tumor cells in the underlying cartilage. However, this patient had a positive SLNB, suggesting that lymphatic spread had already occurred.

Our results support a cartilage-sparing approach for WLE with radial margins consistent with NCCN recommendations. Nationwide, 58% of all melanoma excisions are performed with radial margins less than 1 cm, with even higher nonadherence to margin recommendations in the head and neck region due to cosmetic concerns.^[@bibr5-2473974X20903124]^ Cartilage-sparing excisions allow simple and cosmetically acceptable reconstruction options such as FTSG, and a cartilage-sparing approach may thus preserve reconstructive options to enable oncologic surgeons to more comfortably fully excise the recommended 1- to 2-cm radial margin.

Future work will be required to quantify both the cosmetic and oncologic consequences of cartilage-sparing excision. Patient-reported outcome instruments such as the Patient Outcomes of Surgery-Head/Neck and the FACE-Q Skin Cancer Module have recently begun to quantify outcomes metrics specific to interventions of the head and neck such as patient-perceived facial appearance, appearance-related psychosocial distress, and anxiety regarding cancer recurrence.^[@bibr13-2473974X20903124][@bibr14-2473974X20903124]-[@bibr15-2473974X20903124]^ From an oncologic perspective, assuming 5-year recurrence-free survival in the cartilage-excising group to be 79%,^[@bibr6-2473974X20903124]^ detecting a hazard ratio of 0.8 in favor of cartilage-excising excision over cartilage-sparing resection would require 125 patients in each arm of a potential study. Given the challenges of obtaining such a large number of external ear melanoma cases, continued data aggregation through smaller case series may be the most realistic approach.

Conclusion {#section10-2473974X20903124}
==========

Cartilage-sparing excision for T1 or T2 stage melanoma of the external ear is a surgical option that facilitates reconstruction while allowing 1- to 2-cm radial excision margins. Given the significant functional and aesthetic implications of WLE involving cartilage of the auricle, cartilage-sparing approaches to resection should be considered. Most important, this may increase compliance with achieving the 1- to 2-cm radial margins recommended by the 2016 NCCN guidelines.
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